Sai Life Sciences said the expansion will strengthen its position as a preferred partner for integrated drug development, aligned with the growing demand for end-to-end, partnership-driven solutions that deliver on both quality and timelines.
The investment is part of the company’s planned capital expenditure, reflecting strong business momentum, a robust late-stage development pipeline, and increasing demand for scalable capacity across CMC development and manufacturing.
Krishna Kanumuri, CEO and Managing Director, Sai Life Sciences said, “As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programmes faster and more efficiently through the development continuum.”
It will double double the company’s Process R&D capacity while adding new capabilities in peptide development, oligo intermediates and linkers development, formulation development and early phase clinical supplies.
Spread across 100,000 sq. ft, the upcoming facility will house 140 process chemistry fume hoods with an integrated satellite analytical lab, along with dedicated laboratories for peptides, oligo intermediates, and linkers, the company informed the exchanges.
It will also feature a 25,000 sq. ft. centralized analytical laboratory, NCE formulation development and early-phase clinical supply capabilities, and a kilo lab for early clinical manufacturing.
The new center is designed to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling flexible collaboration with global innovators from early development to late-stage CMC programs.
Based in Telangana, Sai Life Sciences is a Contract Research, Development, and Manufacturing Organizations (CRDMO).
Shares of the company closed 2.01% lower at ₹877.10 on Monday (October 27) on the NSE.
First Published: Oct 27, 2025 4:27 PM IS
